Working toward a mechanism and building on the work of others, 76 Hosobuchi and colleagues 25 would show higher levels of β-endorphins during PAG stimulation. These Keifer et al.
INTRODUCTION
The use of electrical stimulation as a neurosurgical tool is rooted firmly in the history of treating hypokinetic and hyperkinetic disorders. Its emergence was directly related to the use of neurosurgical interventions that included lesions to the thalamus and fibers projecting to and from the thalamus as a treatment of motor signs like rigidity, bradykinesia, and tremor. [1] [2] [3] [4] [5] [6] Although promising, these results were overshadowed by the introduction of L-Dopa as a method for treating Parkinson disease. 7 The use of chronic intracranial stimulation for the treatment of neurologic disorders would remain nearly quiescent for nearly 2 decades until 1987, when Benabid and colleagues 8 reintroduced thalamic stimulation for Parkinson patients who had emerging symptoms after a unilateral thalamotomy. The renaissance of intracranial chronic stimulation further flourished after Parkinson patients on chronic L-Dopa developed adverse side effects. 9, 10 From there, the 1990s through the present would see a strong reemergence of the use of chronic stimulation in hyperkinetic and hypokinetic disorders with targets including the subthalamic nucleus, globus pallidus internus, and ventral intermediate thalamus (Vim). [11] [12] [13] [14] Embedded within the success story of deep brain stimulation (DBS) for movement disorders is the use of chronic intracranial stimulation as an intervention for pain. The work of Heath and Mickle in the 1950s is often thought of as the birth of intracranial stimulation for pain control. Their observation that septal stimulation acutely alleviated intractable pain would lead to the birth of the field. From there, DBS targets for pain control would expand to include the internal capsule (IC), the ventral posterolateral nucleus (VPLP) and the ventral posteromedial nucleus (VPM) of the sensory thalamus (STH), the centro-median parafasicular region (CM-Pf) of the thalamus, the periaqueductal/paraventricular gray (PAG/ PVG), the posterior hypothalamus (PH), the motor cortex, the nucleus accumbens (NAcc), and the anterior cingulate cortex. The following sections highlight the past, present, and future DBS targets used to treat various types of pain.
INTRACRANIAL TARGETS
Within each target section is a brief review of the history behind stimulating the area for pain, the current literature surrounding its use as a target, and the current clinical standing of that area. Tables present a summarized account for the literature on each region. Each entry is based on the information reported in the article with no attempts to standardize terminology across studies. In other words, independent criteria for "successful treatment" (most reports will define this as >50% improvement of their outcome measure), "side effects" (listed side effects only pertain to stimulation, not due to the surgery or postoperative care), or "pain type" (details of patients conditions and source of pain) have not been defined. Several reports included stimulation to multiple targets for pain (eg, a patient will have electrodes placed in the VPLP/VPM and PVG/PAG). These articles are listed once in the table corresponding to the target used for most patients but are noted in the charts for the other brain areas. The notes section of the table contains an abbreviated accounting of other areas stimulated and any additional aspects of the article that should be considered.
Septal Interventions
The stimulation of the septal region of the human brain ( Table 1) was first initiated by Heath and Mickle 15 likely based on the rewarding (or "pleasurable") effects seen in rats. 20 In their work, Heath and Mickle noted that most patients with septal stimulation were more alert and spoke more rapidly. In addition, a few patients were also acutely relieved of their chronic pain (pain due to either rheumatoid arthritis or advanced carcinoma). Later work stimulating the medial forebrain bundle in patients with terminal carcinoma also echoed these results. 16 In particular, Ervin and colleagues 16 stimulated the medial forebrain bundle, among many other areas, and noted an amelioration of the pain reported in their patients with cancer. Because the medial forebrain bundle is part of the mesolimbic pathway, including ventral tegmentum, and NAcc, and also connects to septal nuclei, it is not clear what part of the "pleasure system" could be generating these results. More directly, Gol 17 attempted to study the effects of septal stimulation on pain further and showed some success in a few patients but not the majority (2 of 6 patients). Given these early challenges and only moderate success, it appears that the septum has fallen out of favor. However, it should be noted that 2 works have been published by Schvarcz 18, 19 that suggest a nearly 60% success rate of intractable pain relief with septal stimulation. Currently, septal targeting is not common and there is not a double-blind, randomized, placebo-controlled trial to evaluate it efficacy.
Their results would later expand to a case series. 22 These results would be further bolstered by other groups in the late 1970s to mid-1980s. 23, 28, 29 Interestingly, the notion of stimulating the IC for pain would remain dormant for more than 2 decades until Franzini and colleagues 32 reported a case study in 2008. As of late, Plow and colleagues 33 have published their clinical trial design for stimulation of the ventral striatum and anterior limb of the internal capsule. Although the proposal by Plow and colleagues 33 is not the first clinical trial for the treatment of pain with DBS, it does hold a great deal of promise because it improves several limitations of older clinical trials (discussed later in the Consideration for Trial Design Section).
STH, VPM/Lateral Nucleus Interventions
Primary literature focusing on the treatment of intractable pain with STH stimulation ( Table  3) dates to the early 1970s. Inspired by the results of VPM lesions, 73 the gate control theory of pain, 74 and the paresthesias noted by Ervin, 16 the often cited paper by Hosobuchi and colleagues 34 would involve the treatment of facial anesthesia dolorosa with stimulation of the VPM nucleus of the thalamus. They noted success in 4 of 5 patients. That year and a year later, Mazars and colleagues 35, 36 published their work (started in the early 1960s) on treating intractable pain with thalamic stimulation with 13 of 17 patients showing benefit. Expanding more broadly to chronic neuropathic pain in general, Turnbull and colleagues 39 showed complete or partial success in 14 of 18 patients (including cases of complex regional pain syndrome, lumbar arachnoiditis, phantom limb pain, and plexus avulsion) when stimulating the ventral posterior portion of the thalamus. During these early studies, it was noted that some patients showed an acute relief of pain with VPM/VPLP stimulation, but that the pain would recur gradually. Several attempts would be made to prevent stimulation tolerance. In the peri(aqueductal)ventricular gray (PV[A]G) literature, Hosobuchi 75 would propose the use of L-tryptophan, and Meyerson and colleagues 76 would propose the use L-Dopa to prevent the reduction of the DBS effect. Tsubokawa 26, 27 would pay particular attention to this phenomenon as he further explored VPLP stimulation over several studies. He would introduce the use of L-Dopa and L-Tryptophan supplements in thalamic stimulation to help mitigate the appearance of "stimulation tolerance," although this practice would not continue because of the lack of evidence for efficacy. Interestingly, stimulation tolerance is still a very real concern and is only further compounded with current work that has suggested that there is also an insertional effect (benefit with electrode insertion but no stimulation, as opposed to a developing tolerance to stimulation 66 ).
The late 1980s and early 1990s would show the first attempts by neurosurgeons to summarize their cases with DBS of the VPLP/VPM and PVG/PAG. 47, 50 These results would, for the first time, cast some doubt on the efficacy of DBS for pain (eg, previous reports had success rates in the 60%-80% range, and reports in this era would document long-term success in the 30%-40% range). They would also come at a time when the US Food and Drug Administration (FDA) ruled that DBS devices must be undergo evaluation for safety and efficacy with chronic pain. 77 To add further complication, this ruling would come out at nearly the same time as the retirement of older-generation Medtronic 4 contact platinum electrodes (3380); hence, the appearance of a newer model (thinner diameter and more narrowly spaced contacts) in the literature (3387). Therefore, 2 clinical trials were conducted to evaluate the use of DBS electrodes for the treatment of chronic, intractable pain (1993 was the final report on model 3380, 1999 for 3387). Summarized years later in 2001, Coffey and colleagues 77 would evaluate the new and older electrodes (3380 and 3387) across 2 centers with 246 patients in a prospective clinical trial. The results for VPLP/VPM and PVG/PAG stimulation were disappointing. In the case of the model 3380 electrode trial, only 46.1% of patients showed greater than 50% improvement at 12 months, which dropped to 17.8% at 24 months. The 3387 numbers were even more disheartening with only 16.2% showing greater than 50% pain relief at 12 months and only 13.5% at 24 months (note that withdrawals were counted as failures with these calculations).
Fortunately, despite Medtronic not pursuing FDA approval for DBS electrode use for intractable pain patients, several studies have been published in the interim showing some efficacy of STH stimulation in specific situations. 61, 65, 78 Currently, the STH is often cotargeted with the PVG/PAG areas as first studied by Hosobuchi. 44 The most recent work for DBS stimulation of the STH for pain control suggests that the VPLP/VPM should be considered a second-line treatment target if PAG/PVG stimulation should fail. 71 A wellpowered, double-blind, randomized, placebo-controlled trial has yet to occur.
CM-Pf Interventions
The CM-Pf intralaminar complex of the thalamus has a small history of stimulation for the control of pain ( Table 4) . A comprehensive review of the potential for the CM-Pf is provided by Weigel and Krauss, 83 while the evidence in patients was mostly driven by Andy, 79, 80 with a more recent interest by Krauss and colleagues. 82 Given the recent resurgence of exploring different neurosurgical targets for intractable, chronic pain control, this area may be of future interest.
P(A)VG Interventions
Boethius and colleagues 24 and Richardson and Akil [84] [85] [86] used previous work in animals [87] [88] [89] as evidence to target the PAG and PVG ( Table 5 ) for alleviation of chronic and acute pain. 99 For Richardson and Akil, of the 6 patients they tested, 5 patients had the electrode traversing the PVG alongside the medial aspect of the nucleus parafascicularis. Of these 5 patients, 3 patients (phantom limb pain, carcinoma-related pain, and thalamic pain syndrome) showed good-to-excellent reduction in pain. 84 In the course of their study, they noted that stimulation of the PAG also resulted in pain reduction, albeit at the cost of increased side effects, including nystagmus, vertigo, and nausea. Their follow-up work included chronic implantation of electrodes targeting the PVG for patients with chronic intractable pain. Of these 8 patients, 7 patients (lumber disc disease, carcinoma, brachial plexus avulsion, spine/back/hip injury, pancoast tumor) showed fair to good results (the eighth patient was addicted to narcotics and did not complete the study). 85 In complementary work, Hosobuchi and colleagues 90 showed that PAG stimulation was effective in 6 patients (3 carcinoma pains, 1 diabetic neuropathy, 1 sacral chordoma, and 1 facial anesthesia dolorosa, albeit the latter had more relief with fifth VPM stimulation). results, in combination with studies, noted that the benefits of DBS for pain could be reversed by the opioid antagonist 76,90,100 naloxone, and an opioid-mediated mechanism was put forth. However, ultimately, further studies would not replicate the effect, changes in βendorphin levels were attributed to contrast agents casting doubt on this as a mechanism. 27, 51, 101, 102 Despite that lack of a cogent mechanism, PV(A)G stimulation use as a therapeutic tool for intractable chronic pain would continue to increase. As noted in the STH section, PV(A)G stimulation was often combined or compared with stimulation in other areas. This stimulation has led to the assertion that stimulation of the PAG/PVG is preferred in cases of somatogenic pain, and the STH is preferred in cases of neurogenic pain. 44 As a review of the PAG/PVG and STH charts clearly shows, this assertion is only partially consistent with the evidence.
Like the STH stimulation, PAG/PVG was evaluated in the clinical trials reported by Coffey, 77 although the data were not parsed by stimulation site, limiting any definitive conclusions. Importantly, since that time, many studies have attempted to address the efficacy of PAG/PVG stimulation better. 62, 70, 71, [96] [97] [98] These studies include a randomized, placebo-controlled, N-of-1 series by Green and colleagues 96 and a meta-analysis by Bittar and colleagues, 97 both having favorable conclusions on the use of DBS for chronic intractable pain. A well-powered, double-blind, randomized, placebo-controlled trial has yet to be done.
PH Interventions
In the following section, reports on stimulation of the PH and surrounding area for the treatment of cluster headaches are briefly reviewed ( Table 6 ; for a more comprehensive review of the specific topic, see Magis and Schoenen, 2012 116 ). In expanding on the conventional targets of DBS for pain, Leone and colleagues 103, 104 and Franzini and colleagues 105 reported that stimulation of the PH (targeted based on the circadian and hormonal findings with cluster headaches 117 ) helped ameliorate cluster headache-related pain. Of the 5 patients reported, 2 were able to receive stimulation only and 3 were on lower doses of analgesic medication. They further expanded their findings a year later to 8 patients: 3 requiring no medication and 5 requiring low doses of methysergide and verapamil. 106 They would provide further evidence of the success of the treatment of a rare disorder known as short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, which would be corroborated by another case report. 118 Table 6 documents their growing cohort of patients, 109 including attempts to treat atypical facial pain, where stimulation of the PH was unsuccessful in 3 patients. 110 In addition, other groups would publish their results for stimulating the posterior thalamus for cluster headaches, mostly showing positive results, 107, 111, 112 although there were also notable failures. 113 Given the calls for a larger, well-controlled, double-blind clinical trials, Fontaine and colleagues 114 would report on 11 patients in a prospective crossover, double-blind, multicenter study assessing the efficacy and safety of unilateral hypothalamic DBS in cluster headaches. Interestingly, during the 1-month randomization phase, there were no differences in primary or secondary outcomes between those with and without stimulation. In the following open phase of the trial over the course of 10 months, however, there was notable success in 60% of the patients (in keeping with previous reports). Although the reasons for the discrepancy are not clear, the authors postulate that the rather short period (1 month) of randomization at the start of the trial may have been too brief because the effect is thought to take weeks to over a month. Second, the report stated that default stimulation parameters were used, whereas efficiency was only higher after highly individualized and exhaustive measures were taken to tune the stimulation parameters. Third, they noted higher variability than expected in their primary outcome measures, suggesting their study was underpowered.
In an interesting follow-up using the same patients, Fontaine and colleagues 119 determined the anatomic localization of their placed electrodes using computed tomography and magnetic resonance imaging, determining that effective placements (using coordinates of studies listed in the chart) tended to be more posterior than the hypothalamus. In the 5 responders of the cohort of 10, structures located less than 2 mm from the centers of effective contacts were as follows: the mesencephalic gray substance, the red nucleus, the fascicle retroflexus, the fascicle longitudinal dorsal, the nucleus of ansa lenticularis, the fascicle longitudinal medial, and the thalamus superficialis medial. Revising their coordinates, Seijo and colleagues 115 modified their targeting to include the PH (additionally the stimulation area included the fasciculus mammillotegmentalis, the fasciculus mammillotegmentalis, and the fasciculus medialis telencephali). Using this targeting with 5 patients, an average of 54 days were used to optimize parameters, resulting in 2 patients becoming completely pain free, 2 having a reduction of more than 90%, and 1 having a reduction of attacks to half of the original value. In terms of long-term follow-up, Piacentino and colleagues 120 recently reported on 4 patients who had greater than a 50% decrease in pain intensity perception for more than 5 years. Clearly, the results are optimistic, although a better powered clinical trial is necessary to be conclusive.
Motor Cortex Interventions
Expanding beyond "deep brain" structures, Tsubokawa and colleagues 121 noted particular difficulty with VPLP and IC stimulation in thalamic syndrome patients and therefore pursued the stimulation of the cortex, particularly precentral and postcentral, to evaluate their potential for treatment of chronic pain. In a study of 11 patients with thalamic syndrome, they were able to show an improvement in the pain acutely in 8 of these patients, with 3 of those patients losing efficacy by 2 years. Since that time, research into motor cortex stimulation (MCS) has expanded drastically. This is addressed in the article by Ostergard and colleagues, "Motor Cortex Stimulation for Chronic pain" in this issue.
Other Areas
Along the course of DBS for chronic pain, a few other areas have been targeted for stimulation. In the mid-1980s, Katayama and colleagues 122 presented work on the successful stimulation of the pontomesencephalic parabrachial region for the alleviation of pain in 2 patients with cancer pain. Also, in the parabrachial region, in 1992, Young and colleagues 123 would stimulate the Kolliker Fuse nucleus, showing relief of pain in 3 of the 6 patients. However, there is no clear follow-up work on targeting the parabrachial region for DBS to alleviate chronic pain. More recently, Mallory and colleagues 124 targeted the NAcc ventral striatum in a case report of central poststroke pain, noting success when combining NAcc stimulation with commiserate PV(A)G stimulation (although they report stimulating the NAcc alone helps alleviate pain). Finally, targeting the affective components of pain, Boccard and colleagues 125 recently reported success when stimulating the anterior cingulate cortex of a patient with neuropathic pain.
CONSIDERATIONS FOR PATIENT SELECTION AND TRIAL DESIGN
Given that the evidence for the use of chronic intracranial stimulation for the control of pain is still controversial, there is a clear need for well-designed and executed clinical trials. The aforementioned studies have highlighted a large number of points about researching pain in general and the role of intracranial stimulation specifically.
General Consideration of Pain Research
• There is no well-validated classification scheme for pain; the current use of somatogenic and neurogenic or nociceptive versus neuropathic is helpful, but not necessarily divided along the lines of therapeutic options.
• There is no well-validated and objective method of evaluating pain; current methods rely heavily on subjective reports (see the Visual Analog Scale [VAS] and McGill Pain Questionnaire [MPQ]).
Specific Considerations to Chronic Stimulation for the Treatment of Pain
• The patients used for chronic intracranial stimulation research are already biased because they have failed nearly all other pain-control methods.
• There is no easy way to optimize DBS parameters while also keeping double-blind and placebo-controlled requirements, especially if the stimulation results in a perceivable entity (paresthesias).
• Patients require adjustment of their parameters for optimal effect both in the operating room and during the long-term follow-up.
• Based on a limited pain classification scheme and lack of objective measures, it is hard to understand why patients have successful interventions while others fail.
Importantly, Plow and colleagues 33 have proposed an exciting clinical trial design (NCT01072656) for the use of intracranial stimulation, which includes a much needed control arm that has been absent in many past studies.
SUMMARY
The use of DBS for the control of intractable, chronic pain has a history stretching more than half a century. Within this literature, targets have varied from major white matter tracts like the internal capsule to a specific gray matter island, like the Kolliker Fuse nucleus. Perhaps more impressive, the type and causes of the chronic pain in the patients have been even more diverse from crush injuries to poststroke pain. In lieu of all this variability, it is not surprising that the field still has inconsistent results on the efficacy of DBS for treating pain. 
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As noted, much of the literature is retrospective case reports that leave much to be desired in terms of blinding, controls, and pain measures.
There have been only a few clinical trials, and those have had major limitations. Nevertheless, overall, the preponderance of evidence is in favor of DBS for specific patients. Although many would point to the clinical trials sponsored by Medtronic in the 1990s as a definitive challenge to the use of DBS for pain, it should be noted that those trials were hampered by a lack of enrollment, long-term follow-up, randomization, placebo control, and the inability to address the concerns listed in the general considerations on pain research and specific considerations to chronic stimulation for the treatment of pain sections. Thus, like the studies before those clinical trials, the results are hardly definitive. A major benefit of the publication of the Medtronic trials has been an increase in more rigorous studies being published on the use of DBS with pain. Furthermore, it has encouraged scientists and neurosurgeons to expand beyond the classical brain targets and explore other options within known pain and affective circuits. Finally, and most importantly, more recent and ongoing clinical trials have the promise of being flexible, while rigorous, well-controlled, randomized, and blind, allowing for more definitive conclusions on DBS efficacy in chronic pain treatment.
KEY POINTS
• For more than half a century, neurosurgeons have attempted to treat pain from a diversity of causes using acute and chronic intracranial stimulation.
• Targets of stimulation have included the sensory thalamus, periventricular and periaqueductal gray, the septum, the internal capsule, the motor cortex, posterior hypothalamus, and more recently, the anterior cingulate cortex.
• The current work focuses on presenting and evaluating the evidence for the efficacy of these targets in a historical context while also highlighting the major challenges to having a double-blind placebo-controlled clinical trial.
• Considerations for pain research in general and use of intracranial targets specifically are included. Review of the studies investigating the clinical role for septal stimulation for the treatment of pain
Study, Year Study Type Pain Type Total-(Implanted)-Success Electrode and Stimulation Parameters

Side Effects
Heath & Mickle, 15 Review of the studies investigating the clinical role for internal capsule stimulation for the treatment of pain Table 3 Review of the studies investigating the clinical role for STH stimulation for the treatment of pain Review of the studies investigating the clinical role for centro-median parafascicular complex stimulation for the treatment of pain 
